Abstract: Disclosed herein a composition comprising a urethane of the FIG. 3; where hydroxyl or amine linkages on the urethane of the FIG. 3 are functionalized with molecules that contain fluorine atoms, phosphorus atoms, sulfur atoms, unsaturated carboxylic acids, derivatives of unsaturated carboxylic acids, or combinations thereof. Disclosed herein too is a composition comprising a urethane of the FIG. 3; where hydroxyl or amine linkages of the urethane of the FIG. 3 are functionalized with molecules that contain fluorine atoms, phosphorus atoms, sulfur atoms, unsaturated carboxylic acids, derivatives of unsaturated carboxylic acids, or combinations thereof; and a polymeric resin.

Abstract: A method for preparing 1-adamantyltrimethylammonium methylcarbonate or N,N-dimethyl-3,5-dimethylpiperidinium methylcarbonate is disclosed. The method comprises reacting dimethyl carbonate and 3,5-dimethylpiperidine or a 1-adamantylamine compound and in the presence of water in a sealed vessel at a temperature of from 80 to 200° C. The 1-adamantylamine compound is 1-adamantylamine, 1-adamantylmethylamine, or mixtures thereof.

Abstract: A magnesium compound represented by Formula 1 wherein the magnesium compound is dissolvable in an ether solvent, an electrolyte solution for magnesium batteries that includes the magnesium compound and a magnesium battery including the electrolyte solution are provided: wherein, in Formula 1, X1 is a halogen atom; and at least one of X2 and X3 each independently is an electron withdrawing group, wherein, when X2 or X3 is not an electron withdrawing group, X2 or X3 is a hydrogen atom, a C1-C20 alkyl group, or a C6-C20 aryl group.

Abstract: [Problem] Provision of a novel compound having read-through activity and a drug for the treatment of nonsense mutation-type disease containing this compound. [Solution] A compound represented by the following general formula (1): and a pharmaceutical composition containing this compound.

Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

Abstract: The disclosure provides a diurethane gelator having the structure of Formula I. wherein R1 and R1? each, independently of the other, is a C1-C22 saturated aliphatic hydrocarbon group selected from the group consisting of (1) linear aliphatic groups, (2) branched aliphatic groups, (3) cyclic aliphatic groups, (4) aliphatic groups containing both cyclic and acyclic portions, any carbon atom of the saturated aliphatic hydrocarbon group may be optionally substituted with an alkyl group (cyclic or acyclic), wherein (1) and (2) groups have a carbon number of from about 1 to about 22 carbons, and wherein (3) and (4) groups have a carbon number of from about 4 to about 10 carbons; and X is selected from the group consisting of: (i) an alkylene group, (ii) an arylene group, (iii) an arylalkylene group, and (iv) an alkylarylene group.

Abstract: This invention relates to coating compositions comprising a linear glycidyl carbamate (GC) resin and a curing agent. The linear GC-resins were synthesized using linear and cycloaliphatic diisocyanates and a combination of diols and optional triols with glycidol. The combination of linear diisocyanates and diols introduces a more linear structure in the GC-resin compositions.

Abstract: The invention provides innovative blocked polyisocyanates whose crosslinking is initiated thermally and photochemically. The polyisocyanates comprise at least one thermally reversibly blocked NCO group whose blocking agent contains at least one group which on exposure to actinic radiation reacts, with polymerization, with ethylenically unsaturated compounds. A process for preparing the polyisocyanates, and their use in binders, is also provided.

Abstract: Alkyl and/or alkenyl glycerol carbamate prepared by reacting a carbonate selected from the group consisting of glycerol carbonate, diglycerol carbonate, polyglycerol carbonate and mixtures thereof, with an amine of the general formula (I): HNR1R2??(I) wherein R1 represents a hydrogen atom or a hydrocarbon group selected from the group consisting of alkyl groups and alkenyl groups having from 1 to 22 carbon atoms and R2 represents a hydrocarbon group selected from the group consisting of alkyl groups and alkenyl groups having from 4 to 22 carbon atoms, and cyclic alkyl groups having 5 or 6 carbon atoms, are described along with methods for their use as pearlizing agents in surface-active preparations.

Abstract: An isocyanurate type polyisocyanate composition which is derived from an aliphatic diisocyanate monomer and an alcohol and satisfies all of the following requirements when it contains substantially no aliphatic diisocyanate monomer and substantially no solvent: 1) the viscosity at 25° C. is 500-1,500 mPa·s; 2) the isocyanurate trimer concentration is 60-95 mass %; 3) when the number of allophanate bonds is expressed as A and the number of isocyanurate bonds is expressed as B, the proportion of the allophanate bonds, a=(A/(A+B))×100, is 1-30%; and 4) when the number of urethodione bonds is expressed as D, the proportion of the urethodione bonds, d=(D/(B+D))×100, is less than 2%.

Abstract: The invention relates to a method for preparing a compound comprising at least one ?-hydroxy-urethane unit and/or at least one ?-hydroxy-urethane unit, consisting in reacting a compound (A) comprising at least one cyclocarbonate reactive unit with a compound (B) comprising at least one amino reactive unit (—NH2) in the presence of a catalyst. The invention also relates to the use of a catalyst comprising at least one organometallic complex and a co-catalyst chosen from the group of Lewis bases and/or tetra-alkyl ammonium salts, in order to catalyse the method of the invention. The invention relates to the technical field of preparing urethane derivatives.

Abstract: The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.

Abstract: Disclosed herein are compounds useful in the preparation of non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are compounds useful in the preparation of non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such resultant polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

Abstract: A resin crosslinking agent that is capable of enhancing the scuffing resistance and the chemical resistance upon adding a carbodiimide compound as a crosslinking agent to an aqueous resin. The resin crosslinking agent contains: a carbodiimide compound having at least one carbodiimide group, having terminals that are capped with at least one compound (hydrophilic organic compound I) selected from a dialkylamino alcohol, a hydroxycarboxylic acid alkyl ester and a (poly)alkylene glycol monoalkyl ether, and with a compound (hydrophilic organic compound II) that has higher hydrophilicity than the hydrophilic organic compound I and has at least one hydroxyl group; and a water-miscible liquid compound.

Abstract: A urethane adhesive composition includes a first liquid and a second liquid, the first liquid containing a prepolymer obtained by reacting a polyisocyanate and a high-molecular-weight polyol (I), and at least one filler selected from talc and calcium carbonate, and containing 20 parts by mass or more of talc, 0 to 40 parts by mass of calcium carbonate, and 10 parts by mass or more of zeolite based on 100 parts by mass of the polyisocyanate, the high-molecular-weight polyol (I), and the prepolymer in total, the second liquid containing a high-molecular-weight polyol (II) and a low-molecular-weight polyol, the ratio of the number of moles of hydroxyl groups derived from the low-molecular-weight polyol to the total number of moles of hydroxyl groups derived from the high-molecular-weight polyol (I) and the high-molecular-weight polyol (II) being four or more.

Abstract: Non-fluorinated blocked polyurethanes are described as extenders and, particularly as textile auxiliaries, for use with fluorochemical polymers in treating substrates, for example fibrous substrates, such as textile fabrics or yarns. The polyurethane is prepared by reacting a polyisocyanate, a blocking agent, and a non-fluorinated isocyanate reactive compound having an average alkyl chain length of 24 to 50 carbon atoms.

Abstract: Catalysts, which are free of tin, are described which are useful in the reaction between an isocyanate and an alcohol, which is a key step for preparing polyurethane polymers. The catalyst is a metal complex or salt of formula (1): [Zn(L1)l1(L2)l2(Y)x]??(1) in which: l1?1 and l2=0 or 1; with l1+l2=2, x=1 or 2, the symbol L1 represents a ligand which is a ?-dicarbonylato anion or the enolate anion of a ?-dicarbonyl compound or an acetylacetato anion derived from a ?-ketoester, when l1=2, the symbols L1 are identical or different, the symbol L2 represents an anionic ligand which is different from L1, and the symbol Y represents a neutral ligand; where the metal complex or salt C of formula (1) is not zinc diacetylacetonate.

Abstract: A method to form a urethane material, the method comprises blending and reacting at least one isocyanate, at least one isocyanate reactive compound and a metallized polyhedral oligomeric silsesquioxane to provide said urethane material, the metallized polyhedral oligomeric silsesquioxane is a dimeric structure with general formula wherein M represents a metal providing a 6-coordinated metal center, x and y being 1, R1O and R2O represent an alkoxide bridging the 6-coordinated metal centers, R3OH and R4OH represent an alcohol ligand and each of R5, to R18 is selected from the group consisting of alkyl-, polyether- and polyester ligands.

Abstract: The disclosure provides a diurethane gelator having the structure of Formula I. wherein R1 and R1? each, independently of the other, is a C1-C22 saturated aliphatic hydrocarbon group selected from the group consisting of (1) linear aliphatic groups, (2) branched aliphatic groups, (3) cyclic aliphatic groups, (4) aliphatic groups containing both cyclic and acyclic portions, any carbon atom of the saturated aliphatic hydrocarbon group may be optionally substituted with an alkyl group (cyclic or acyclic), wherein (1) and (2) groups have a carbon number of from about 1 to about 22 carbons, and wherein (3) and (4) groups have a carbon number of from about 4 to about 10 carbons; and X is selected from the group consisting of: (i) an alkylene group, (ii) an arylene group, (iii) an arylalkylene group, and (iv) an alkylarylene group.

Abstract: Methods of catalyzing chemical reactions are provided. A tri-substituted phosphine having at least one substituent that is an alkyl group is added as a catalyst to reaction mixtures. Reaction mixtures contain uretdiones, anhydrides, or isocyanate functional materials including isocyanurates, in various combinations with hydroxyl, thiol, and/or amine functional materials. Curable compositions comprising these catalysts and reaction mixtures are also provided.

Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.

Abstract: A magnesium compound represented by Formula 1 wherein the magnesium compound is dissolvable in an ether solvent, an electrolyte solution for magnesium batteries that includes the magnesium compound and a magnesium battery including the electrolyte solution are provided: wherein, in Formula 1, X1 is a halogen atom; and at least one of X2 and X3 each independently is an electron withdrawing group, wherein, when X2 or X3 is not an electron withdrawing group, X2 or X3 is a hydrogen atom, a C1-C20 alkyl group, or a C6-C20 aryl group.

Abstract: Polyol compositions containing methane linkages derived from amino acids. The polyols are obtained from the reaction of the carbonate with the cadres in the amino acids. Individual amino acids or mixtures of amino acids that are prepared from the hydrolysis of the proteins can be used.

Abstract: A method for producing toluenedicarbamate includes a carbamate production process of producing toluenedicarbamate by reaction between toluenediamine, urea, and/or N-unsubstituted carbamic acid ester, and alcohol; and a benzoyleneurea reduction process of reducing a disubstituted benzoyleneurea and a derivative thereof to 10 mol or less relative to 100 mol of toluenedicarbamate, wherein the disubstituted benzoyleneurea is represented by formula (1) below and has a methyl group and an amino group:

Abstract: Prepolymers, which are accessible from formamides of low molecular weight di- or triamines (formamide-terminated low molecular weight compounds) and di- or polyisocyanates, of the general formula (II): X—[—N(CHO)—CO—NH—R1—NCO]n??(II) wherein X represents a linear or branched aliphatic, cycloaliphatic, heterocyclic and/or aromatic structural unit having 2 to 40 carbon atoms, and which is optionally further substituted and/or optionally comprises one or more heteroatoms, wherein R1 represents an organic radical which may optionally contain one or more heteroatoms and which may further contain one or more additional free isocyanate groups and/or one or more urethane, biuret, carbodiimide, isocyanurate, allophanate, iminooxadiazinedione and/or uretdione structural units, and wherein n?2; processes for making the same; compositions containing the same; and uses thereof.

Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Abstract: The present invention provides a method for preparing a sample characterized by binding a substance A containing a hydrazide group to a sugar chain and/or a sugar derivative via hydrazone formation between the hydrazide group of the substance A and the reducing end of the sugar chain and/or the sugar derivative thereby to enable the separation and purification of the sugar chain and/or the sugar derivative for an analytical sample from a biological sample containing the sugar chain and/or the sugar derivative by a simple operation.

Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The invention relates to hydroxyl-functionalised polyurethane hot melt prepolymers comprising the chemical reaction product of isocyanate-reactive starting materials with at least one isocyanate-containing starting material. Said prepolymers are characterized in that the isocyanate-reactive starting materials of the hydroxyl-functionalised polyurethane hot melt prepolymers have a polypropylene glycol with a functionality higher than two and a number-average molar mass higher than or equal to 3,000 g/mol, a polypropylene glycol with a functionality less than or equal to two and a number-average molar mass less than or equal to 1,000 g/mol, and a chain lengthener with a functionality less than or equal to 500 g/mol, and the isocyanate-containing starting material of the hydroxyl-functionalised polyurethane hot melt prepolymer has an aliphatic or alicyclic diisocyanate.

Abstract: The instant invention relates to a composition comprising at least one polymer having the structure A-B-A?, wherein A and A? may be the same or different and each is a degradable polyester component and wherein B is the reaction product resulting from the reaction between a diol, having one or more pendant oligomeric or polymeric groups, and A and A?. Additionally, the invention also relates to the development of a bioresorbable patch comprising: (a) an adhesion barrier component comprising a composition according to the invention in the form of a film; and (b) an adhesive component comprising: (i) at least one synthetic adhesive polymer; and/or (ii) at least one polysaccharide. The present invention provides a method of wound healing, comprising administering the composition or patch.

Abstract: Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.

Abstract: An oligomer is made by capping a uretdione compound of structure with a compound (II) having an active hydrogen and a carbamate or cyclic carbonate group under conditions in which the isocyanate groups but not the uretdione group react. The product (III) is either reacted with a reactant having at least two active hydrogens under reaction conditions that cleave the uretdione ring, after which any cyclic carbonate groups may be converted to carbamate groups, or a product (III) having cyclic carbonate groups is reacted with ammonia or primary amine to provide uretdione with a hydroxy carbamate group that is then self-condensed under uretdione ring-opening conditions. A curable coating composition comprises the oligomer; a coated article is prepared by applying a layer of the curable coating composition and curing the applied layer.

Abstract: The invention relates to a wetting and dispersing agent that can be produced by carrying out step (1): wherein a) an organic polymer containing primary and/or secondary amino groups and h) at least one branched polyhydroxymonocarboxylic acid comprising, in addition to a carboxyl group, at least two hydroxy groups, one of which is not bound to the main chain of the molecule, are reacted by condensation reactions, forming amide linkages; and step (2): wherein at least some of the hydroxy groups of the hydroxy-functional reaction product obtained in step (1) are reacted with at least one organic monoisocyanate, forming urethane linkages.

Abstract: The invention provides a method to produce a stable, ionic-bonded, dry creatine-?-ketoglutarate product at a molar ratio of about 2:1. The product is stable at room temperature when kept dry for periods of up to one year. The product can be supplemented with additional biologically active, natural amino acid, preferably l-arginine, l-taurine and l-citrulline. The serving dosage is typically between about 1 and 2 g.

Abstract: Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed. One preferred compound is Methods of making and using the compounds and conjugates described herein are also provided.

Abstract: Prepolymers are prepared by a reaction of a polyisocyanate and a hydroxylmethyl containing polyester polyol derived from a fatty acid. The prepolymers can be prepared having isocyanate, hydroxyl, or a variety of other reactive functional groups. The prepolymers are useful in making polyurethanes and other polymers, or a crosslinking agents.

Abstract: A coating film forming composition includes an amino acid generator including a protecting group that is eliminated to generate an amino acid. A coating film forming composition includes a component (A): the amino acid generator; a component (B): a hydrolyzable silane, a hydrolysis product thereof, a hydrolysis-condensation product thereof, or a mixture thereof; and a component (C): a solvent.

Abstract: Disclosed is a compound having a photocurable urethane (meth)acrylate group, its manufacturing method, and a photocurable composition including the compound. The compound is represented by Chemical Formulae 1 to 6. Each of Chemical Formulae 1 to 6 includes a urethane (meth)acrylate group represented by Chemical Formula 1-1 or 1-2.

Abstract: A polyurethane or polyurea coating for use in protecting a leading edge substrate on an airfoil against liquid or solid particle erosion, the composition made from an isocyanate-terminated prepolymer and curing agents, such as polyaspartic esters, aldimines and ketimines with optional flatting agent for matte coatings.

Abstract: The invention is directed to a polymerizable composition containing: a compound containing a repeating unit having a polyether structure having a fluorine atom and four or more polymerizable groups and being represented by the formula (I) as defined herein; a photopolymerization initiator; and an organic solvent, or a polymerizable composition containing: a compound containing a repeating unit having a polyether structure having a fluorine atom and four or more polymerizable groups and being represented by one of the formulae (I-1) to (I-5) as defined herein; a photopolymerization initiator; and an organic solvent.

Abstract: The invention relates to compounds, of formula (I) in which X is CH3 or hydrogen, Z is a linear or branched C2 to C4 alky radical, R is a linear or branched, optionally heteroatom-substituted aliphatic, aromatic or araliphatic radical, Y in each occurrence is independently hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, chlorine, bromine, iodine, methylthio, phenyl or phenylthio, n is from 0 to 4 and m is from 0 to 5. The invention further relates to the use of such a compound as writing monomer in a photopolymer formulation. In addition, a photopolymer formulation comprising as least a polyisocyanate component, a polyol component, a photoinitiator and a compound of formula (I) as writing monomer, and also the use of the photopolymer formulation for producing holographic media, are likewise subjects of the invention.

Abstract: A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of ?4?1, ?5?1, ?4?7, ?v?3 and ?L?2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

Abstract: A polyether polyol composition comprising: a polyether polyol, a phosphoric acid compound selected from the group consisting of at least one of orthophosphoric acid, polyphosphoric acid, polymetaphosphoric acid, and partial esters thereof in an amount raning from 0.5 to 100 ppm based on the polyether polyol metals derived from a composite metal cyanide complex catalyst in an amount ranging from 1 to 30 ppm based on the polyether polyol; a method for producing this polyether polyol composition; and methods of making polyurethane or isocyanate group-terminated prepolymers.

Abstract: The invention relates to addition compounds which are obtainable by reacting a) one or more polyisocyanates containing uretdione groups with b) one or more compounds of the formula (I) Y—(XH)n??(I) with the proviso that at least 50% of the free isocyanate groups of component a) are reacted with the compounds of the formula (I) to give an intermediate which contains uretdione groups, and subsequently the intermediate is reacted with c) one or more compounds of the general formula (II) Z—NHRm??(II) with the proviso that all free NCO groups optionally still present and at least 20% of uretdione groups originally used are reacted with Z—(NHR)m. The invention further relates to the use of the addition compounds as dispersants and dispersion stabilizers, and to a process for preparing them.

Abstract: The invention provides a method to produce a stable, ionic-bonded, dry creatine-?-ketoglutarate product at a molar ratio of about 2:1. The product is stable at room temperature when kept dry for periods of up to one year. The product can be supplemented with additional biologically active, natural amino acid, preferably l-arginine, l-taurine and l-citrulline. The serving dosage is typically between about 1 and 2 g.

Abstract: Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure wherein Z is a moiety that can be activated for attachment to biologically active molecules such as proteins and wherein P and Q represent linkage fragments that join polymer arms polya and polyb, respectively, to central carbon atom, C, by hydrolytically stable linkages in the absence of aromatic rings in the linkage fragments. R typically is hydrogen or methyl, but can be a linkage fragment that includes another polymer arm. A specific example is an mPEG disubstituted lysine having the structure where mPEGa and mPEGb have the structure CH3O—(CH2CH2O)nCH2CH2— where n may be the same or different for polya- and polyb- and can be from 1 to about 1,150 to provide molecular weights of from about 100 to 100,000.

Abstract: The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.

Abstract: The present invention relates to a process for preparing polyisocyanates by oligomerization of isocyanates.

Abstract: The invention relates to a carbodiimide compound or mixture of carbodiimide compounds derived from a carbodiimidization reaction of at least one oligomer having at least one isocyanate group and comprising at least two repeating units deriving from one or more ethylenically unsaturated monomers.

Abstract: A method for producing toluenedicarbamate includes a carbamate production process of producing toluenedicarbamate by reaction between toluenediamine, urea, and/or N-unsubstituted carbamic acid ester, and alcohol; and a benzoyleneurea reduction process of reducing a disubstituted benzoyleneurea and a derivative thereof to 10 mol or less relative to 100 mol of toluenedicarbamate, wherein the disubstituted benzoyleneurea is represented by formula (1) below and has a methyl group and an amino group: